Is nanomedicine still promising?

Pubudu M. Peiris; Efstathios Karathanasis

doi:10.18632/oncotarget.295

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial Introducing OncoTarget.

Request Conference Sponsorship

Editorial Comments:

Is nanomedicine still promising?

Pubudu M. Peiris and Efstathios Karathanasis _

PDF | HTML | How to cite | Order a Reprint

Oncotarget. 2011; 2:430-432. https://doi.org/10.18632/oncotarget.295

Metrics: PDF 1392 views | HTML 2263 views | ?

Abstract

Commentary on: Mann AP et al. Oncotarget. 2011; 2:298-304.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 295

Subscribe to TOC Alerts

Editorial Comments:

Is nanomedicine still promising?

Abstract